BHCM
UTHR icon

Boulder Hill Capital Management’s United Therapeutics UTHR Stock Holding History

Boulder Hill Capital Management’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-1,600
Closed -$358K – 175
2023
Q1 		$358K Buy
+1,600
New +$394K 0.29% 73
2022
Q4 		– Sell
-4,200
Closed -$879K – 218
2022
Q3 		$879K Buy
+4,200
New +$939K 0.67% 29

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Boulder Hill Capital Management's UTHR Position: Q2 2023 in Review

Boulder Hill Capital Management sold out of United Therapeutics (UTHR) in Q2 2023, closing a stake of 1,600 shares — an estimated $358K sold.

Boulder Hill Capital Management first reported a position in UTHR in Q3 2022 and held it in 2 quarters. The position peaked at $879K in Q3 2022. 473 funds tracked by Wall St. Rank hold UTHR as of Q2 2023.

  • Boulder Hill Capital Management reported no remaining United Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Boulder Hill Capital Management sold 1,600 United Therapeutics shares in Q2 2023, an estimated $358K.
  • Boulder Hill Capital Management first reported a position in United Therapeutics in Q3 2022 and held it in 2 quarters.
  • Boulder Hill Capital Management's United Therapeutics position peaked at $879K in Q3 2022.
  • 473 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2023.

Based on Boulder Hill Capital Management's 13F filing for Q2 2023, filed 11 Aug 2023.